IL6 and neoplasm: Accordingly, we found that (+)-JQ1 administration significantly (p < 0.0001, one-way ANOVA) reduced IL6 circulating levels, which were significantly (p < 0.0001, one-way ANOVA) elevated in tumor-bearing mice treated with either vehicle or (−)-JQ1, when compared to control mice (Fig. 5e).